ENO2 and neoplasm: To further clarify the relationship of clinical efficacy with the positive rates of NSE and CYFRA21-1 before treatment, we recorded as tumor maker positive TM(+) when neither NSE or CYFRA21-1 was positive before treatment, and as TM(-) when both were negative.